Beyond immunoradiotherapy, we assessed the therapeutic efficacy of MerTK ASO in combination with chemotherapy, selumetinib, and either anti-PDL1 or anti-PD1 across different tumor models (Supplemental Fig. S2). This evidence concerns the gene CD274 and neoplasm.